Articulinx closes $10M Series B financing round Articulinx.

‘Articulinx has made significant progress in a very capital efficient manner which is crucial in this funding environment,’ stated Dr. Jonathan Root, General Partner at USVP. ‘We are pleased to have the opportunity to purchase Articulinx as we function to address an extremely large and underserved marketplace.’ Osteoarthritis can involve multiple joints in the physical body causing pain, limited range of motion, and disability and happens to be incurable. Happening most in the hand commonly, it could impact many areas of daily living severely.. Articulinx closes $10M Series B financing round Articulinx, Inc., a medical device company developing a novel minimally-invasive approach for the treating osteoarthritis, announced today the closing of a $10M Series B funding led by US Venture Partners .Our ‘D-peptides’ present many potential therapeutic advantages over existing peptide access inhibitors, which are expensive, require high dose injections, and suffer from the emergence of drug-level of resistance, said University of Utah biochemist Michael S. Kay, lead writer on the paper. In contrast, our D-peptides withstand degradation, so they possess the potential to become administered orally and last longer in the bloodstream. Since these inhibitors possess a unique inhibitory system, they should work well in combination with existing HIV inhibitors. Related StoriesPitt Public Wellness launches study to promote health among aging gay and bisexual males with HIVNew pc model predicts degrees of HIV care engagementResearch provides leads for new strategies to develop HIV vaccineThe experts were particularly interested in developing medications to bind to an important pocket structure found in all HIV strains that was previously identified as a promising drug target using structures motivated at Brookhaven’s NSLS.